Efficacy and safety of glycemic control in type 2 diabetes patients when switched to mitiglinide/voglibose fixed-dose combination therapy.

Efficacy and safety of glycemic control in type 2 diabetes patients when switched to mitiglinide/voglibose fixed-dose combination therapy. - Efficacy and safety of mitiglinide/voglibose fixed-dose combination therapy.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007619

Enrollment

Registered

2012-04-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Switching from co-administration of a glinide and alpha glycosidase inhibitor to mitiglinide/voglibose fixed dose combination tablet for 16 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with type 2 diabetes who are receiving a combination therapy with glinide and alpha glucosidase inhibitor more than 2 months.

Exclusion criteria

Exclusion criteria: 1) Contraindicated for mitiglinide or voglibose. 2) Patients who received glinide or alpha GI more than daily dose*. (Daily dose: mitiglinide 10mg/time, nateglinide 90mg/time, voglibose 0.3mg/time, acarbose 100mg/time, miglitol 50mg/time) 3) Patients who had been previously receiving DPP4 inhibitor or GLP-1 analogue, insulin. 4) Anticipated to be non-compliant to the trial by principal investigators opinion.

Design outcomes

Primary

Measure	Time frame
%MPR, HbA1c	—

Secondary

Measure	Time frame
1,5-AG, glycoalbumin, serum lipid profile, blood pressure, body weight, hypoglycemia, liver function, DTSQ	—

Countries

Japan

Contacts

Public ContactYoshifumi Saisho

Keio University School of Medicine Department of Nephrology, Endocrinology and Metabolism

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026